Royston Jefferis
Overview
Explore the profile of Royston Jefferis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masuda K, Yamaguchi Y, Takahashi N, Jefferis R, Kato K
FEBS Lett
. 2010 Jul;
584(15):3474-9.
PMID: 20621099
Mutagenesis directed to a specific glycosylation site has been widely used to examine biological roles of individual glycans. However, occurrence of any post-translational modification on such deglycosylated mutants has not...
2.
Hussain A, Pankhurst T, Goodall M, Colman R, Jefferis R, Savage C, et al.
Immunology
. 2009 Sep;
128(2):236-44.
PMID: 19740380
Anti-proteinase 3 antibodies are implicated in the pathogenesis of small vessel vasculitis. These are primarily immunoglobulin G (IgG), with different subclasses predominating at different stages of disease. However, little is...
3.
Jefferis R
Trends Pharmacol Sci
. 2009 Jun;
30(7):356-62.
PMID: 19552968
More than twenty recombinant antibody molecules are now licensed for the treatment of a variety of cancers and chronic diseases. Initially, the attraction of antibodies was their specificity for target...
4.
Colman R, Hussain A, Goodall M, Young S, Pankhurst T, Lu X, et al.
Ann Rheum Dis
. 2007 Jan;
66(5):676-82.
PMID: 17204568
Background: Antineutrophil cytoplasmic antibodies (ANCA) are associated with small-vessel vasculitis and have been implicated in its pathogenesis. The subclass distribution of ANCA IgG deviates from normal patterns, and it has...
5.
Jefferis R
Biotechnol Prog
. 2005 May;
21(1):11-6.
PMID: 15903235
The adaptive immune system has the capacity to produce antibodies with a virtually infinite repertoire of specificities. Recombinant antibodies specific for human targets are established in the clinic as therapeutics...
6.
Watt G, Lund J, Levens M, Kumar Kolli V, Jefferis R, Boons G
Chem Biol
. 2003 Oct;
10(9):807-14.
PMID: 14522051
A range of well-defined IgG glycoforms was prepared by employing a combination of synthetic carbohydrate chemistry and genetic engineering. The key aspect of this methodology is the coupling of thioaldoses...